Kadmon Holdings, Inc.:
Lead candidate is KD025, a ROCK2 inhibitor in in a pivotal clinical trial for chronic graft-versus-host disease (cGVHD); study outcome to be reported by YE 2019. Ph2 trial of KD025 in systemic sclerosis ongoing. Also developing KD033, anti-PD-L1/IL-15 fusion protein; exp to enter the clinic Q4 2019. FDA approval received Sept 2019 for Wilson's disease indication (generic trientine capsules).
Phase l or ll
Autoimmune, Fibrosis, Oncology
100MM - 500MM
450 East 29th Street
New York, NY 10016
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by